| 1Q2W | A:; B: | X-RAY CRYSTAL STRUCTURE OF THE SARS CORONAVIRUS MAIN PROTEASE |
| 1UJ1 | A:; B: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEINASE (3CLPRO) |
| 1UK2 | A:; B: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEINASE (3CLPRO) AT PH8.0 |
| 1UK3 | A:; B: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEINASE (3CLPRO) AT PH7.6 |
| 1UK4 | A:; B: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEINASE (3CLPRO) COMPLEXED WITH AN INHIBITOR |
| 1Z1I | A: | CRYSTAL STRUCTURE OF NATIVE SARS CLPRO |
| 1Z1J | A:; B: | CRYSTAL STRUCTURE OF SARS 3CLPRO C145A MUTANT |
| 2A5A | A: | CRYSTAL STRUCTURE OF UNBOUND SARS CORONAVIRUS MAIN PEPTIDASE IN THE SPACE GROUP C2 |
| 2A5I | A: | CRYSTAL STRUCTURES OF SARS CORONAVIRUS MAIN PEPTIDASE INHIBITED BY AN AZA-PEPTIDE EPOXIDE IN THE SPACE GROUP C2 |
| 2A5K | A:; B: | CRYSTAL STRUCTURES OF SARS CORONAVIRUS MAIN PEPTIDASE INHIBITED BY AN AZA-PEPTIDE EPOXIDE IN SPACE GROUP P212121 |
| 2ALV | A:2-301 | X-RAY STRUCTURAL ANALYSIS OF SARS CORONAVIRUS 3CL PROTEINASE IN COMPLEX WITH DESIGNED ANTI-VIRAL INHIBITORS |
| 2C3S | A: | STRUCTURE OF SARS COV MAIN PROTEINASE AT 1.9 A (PH6.5) |
| 2DUC | A:; B: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEINASE(3CLPRO) |
| 2GT7 | A:; B: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PEPTIDASE AT PH 6.0 IN THE SPACE GROUP P21 |
| 2GT8 | A: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PEPTIDASE (WITH AN ADDITIONAL ALA AT THE N-TERMINUS OF EACH PROTOMER) IN THE SPACE GROUP P43212 |
| 2GTB | A: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PEPTIDASE (WITH AN ADDITIONAL ALA AT THE N-TERMINUS OF EACH PROTOMER) INHIBITED BY AN AZA-PEPTIDE EPOXIDE IN THE SPACE GROUP P43212 |
| 2GX4 | A: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS 3CL PROTEASE INHIBITOR COMPLEX |
| 2GZ7 | A: | STRUCTURE-BASED DRUG DESIGN AND STRUCTURAL BIOLOGY STUDY OF NOVEL NONPEPTIDE INHIBITORS OF SARS-COV MAIN PROTEASE |
| 2GZ8 | A: | STRUCTURE-BASED DRUG DESIGN AND STRUCTURAL BIOLOGY STUDY OF NOVEL NONPEPTIDE INHIBITORS OF SARS-COV MAIN PROTEASE |
| 2GZ9 | A: | STRUCTURE-BASED DRUG DESIGN AND STRUCTURAL BIOLOGY STUDY OF NOVEL NONPEPTIDE INHIBITORS OF SARS-COV MAIN PROTEASE |
| 2H2Z | A: | CRYSTAL STRUCTURE OF SARS-COV MAIN PROTEASE WITH AUTHENTIC N AND C-TERMINI |
| 2HOB | A: | CRYSTAL STRUCTURE OF SARS-COV MAIN PROTEASE WITH AUTHENTIC N AND C-TERMINI IN COMPLEX WITH A MICHAEL ACCEPTOR N3 |
| 2OP9 | A:; B: | SUBSTRATE SPECIFICITY PROFILING AND IDENTIFICATION OF A NEW CLASS OF INHIBITOR FOR THE MAJOR PROTEASE OF THE SARS CORONAVIRUS |
| 2PWX | A: | CRYSTAL STRUCTURE OF G11A MUTANT OF SARS-COV 3C-LIKE PROTEASE |
| 2Q6G | A:; B: | CRYSTAL STRUCTURE OF SARS-COV MAIN PROTEASE H41A MUTANT IN COMPLEX WITH AN N-TERMINAL SUBSTRATE |
| 2QC2 | A:; B: | CRYSTAL STRUCTURE OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) 3C-LIKE PROTEASE ASN214ALA MUTANT |
| 2QCY | A: | CRYSTAL STRUCTURE OF A MONOMERIC FORM OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) 3C-LIKE PROTEASE MUTANT |
| 2QIQ | A: | STRUCTURE-BASED DESIGN AND SYNTHESIS AND BIOLOGICAL EVALUATION OF PEPTIDOMIMETIC SARS-3CLPRO INHIBITORS |
| 2V6N | A: | CRYSTAL STRUCTURES OF THE SARS-CORONAVIRUS MAIN PROTEINASE INACTIVATED BY BENZOTRIAZOLE COMPOUNDS |
| 2Z3C | A: | A MECHANISTIC VIEW OF ENZYME INHIBITION AND PEPTIDE HYDROLYSIS IN THE ACTIVE SITE OF THE SARS-COV 3C-LIKE PEPTIDASE |
| 2Z3D | A: | A MECHANISTIC VIEW OF ENZYME INHIBITION AND PEPTIDE HYDROLYSIS IN THE ACTIVE SITE OF THE SARS-COV 3C-LIKE PEPTIDASE |
| 2Z3E | A: | A MECHANISTIC VIEW OF ENZYME INHIBITION AND PEPTIDE HYDROLYSIS IN THE ACTIVE SITE OF THE SARS-COV 3C-LIKE PEPTIDASE |
| 2Z94 | A: | COMPLEX STRUCTURE OF SARS-COV 3C-LIKE PROTEASE WITH TDT |
| 2Z9G | A: | COMPLEX STRUCTURE OF SARS-COV 3C-LIKE PROTEASE WITH PMA |
| 2Z9J | A:; B: | COMPLEX STRUCTURE OF SARS-COV 3C-LIKE PROTEASE WITH EPDTC |
| 2Z9K | A:; B: | COMPLEX STRUCTURE OF SARS-COV 3C-LIKE PROTEASE WITH JMF1600 |
| 2Z9L | A:; B: | COMPLEX STRUCTURE OF SARS-COV 3C-LIKE PROTEASE WITH JMF1586 |
| 2ZU4 | A: | COMPLEX STRUCTURE OF SARS-COV 3CL PROTEASE WITH TG-0204998 |
| 2ZU5 | A: | COMPLEX STRUCTURE OF SARS-COV 3CL PROTEASE WITH TG-0205486 |
| 3ATW | A:; B: | STRUCTURE-BASED DESIGN, SYNTHESIS, EVALUATION OF PEPTIDE-MIMETIC SARS 3CL PROTEASE INHIBITORS |
| 3AVZ | A: | STRUCTURE OF SARS 3CL PROTEASE WITH PEPTIDIC ALDEHYDE INHIBITOR CONTAINING CYCLOHEXYL SIDE CHAIN |
| 3AW0 | A: | STRUCTURE OF SARS 3CL PROTEASE WITH PEPTIDIC ALDEHYDE INHIBITOR |
| 3AW1 | A:; B: | STRUCTURE OF SARS 3CL PROTEASE AUTO-PROTEOLYSIS RESISTANT MUTANT IN THE ABSENT OF INHIBITOR |
| 3D62 | A: | DEVELOPMENT OF BROAD-SPECTRUM HALOMETHYL KETONE INHIBITORS AGAINST CORONAVIRUS MAIN PROTEASE 3CLPRO |
| 3F9E | A: | CRYSTAL STRUCTURE OF THE S139A MUTANT OF SARS-CORONOVIRUS 3C-LIKE PROTEASE |
| 3F9F | A:; B: | CRYSTAL STRUCTURE OF THE F140A MUTANT OF SARS-CORONOVIRUS 3C-LIKE PROTEASE AT PH 6.0 |
| 3F9G | A:; B: | CRYSTAL STRUCTURE OF THE F140A MUTANT OF SARS-CORONOVIRUS 3C-LIKE PROTEASE AT PH 6.5 |
| 3F9H | A:; B: | CRYSTAL STRUCTURE OF THE F140A MUTANT OF SARS-CORONOVIRUS 3C-LIKE PROTEASE AT PH 7.6 |
| 3FZD | A: | MUTATION OF ASN28 DISRUPTS THE ENZYMATIC ACTIVITY AND DIMERIZATION OF SARS 3CLPRO |
| 3M3S | A:; B: | CRYSTAL STRUCTURE OF SARS-COV MAIN PROTEASE ASN214ALA MUTANT WITH AUTHORIZE N-TERMINUS |
| 3SN8 | A: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEASE COMPLEXED WITH CM-FF-H (SOAKING) |
| 3SNA | A: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEASE COMPLEXED WITH AC-NSFSQ-H (SOAKING) |
| 3SNB | A: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEASE COMPLEXED WITH AC-DSFDQ-H (SOAKING) |
| 3SNC | A: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEASE COMPLEXED WITH AC-NSTSQ-H (SOAKING) |
| 3SND | A:; B: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEASE COMPLEXED WITH AC-ESTLQ-H (COCRYSTALLIZATION) |
| 3SNE | A: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEASE COMPLEXED WITH AC-ESTLQ-H (SOAKING) |
| 3SZN | A: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEASE COMPLEXED WITH AN ALPHA, BETA-UNSATURATED ETHYL ESTER SG75 |
| 3TIT | A: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEASE COMPLEXED WITH AN ALPHA, BETA-UNSATURATED ETHYL ESTER SG81 |
| 3TIU | A: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEASE COMPLEXED WITH AN ALPHA,BETA-UNSATURATED ETHYL ESTER INHIBITOR SG82 |
| 3TNS | A: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEASE COMPLEXED WITH AN ALPHA, BETA-UNSATURATED ETHYL ESTER INHIBITOR SG83 |
| 3TNT | A: | CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEASE COMPLEXED WITH AN ALPHA, BETA-UNSATURATED ETHYL ESTER INHIBITOR SG85 |
| 3V3M | A: | SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV) 3CL PROTEASE IN COMPLEX WITH N-[(1R)-2-(TERT-BUTYLAMINO)-2-OXO-1-(PYRIDIN-3-YL) ETHYL]-N-(4-TERT-BUTYLPHENYL)FURAN-2-CARBOXAMIDE INHIBITOR. |
| 3VB3 | A:; B: | CRYSTAL STRUCTURE OF SARS-COV 3C-LIKE PROTEASE IN APO FORM |
| 4HI3 | A:; B: | CRYSTAL STRUCTURE OF DIMERIC R298A MUTANT OF SARS CORONAVIRUS MAIN PROTEASE |
| 4MDS | A: | DISCOVERY OF N-(BENZO[1,2,3]TRIAZOL-1-YL)-N-(BENZYL)ACETAMIDO)PHENYL) CARBOXAMIDES AS SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV) 3CLPRO INHIBITORS: IDENTIFICATION OF ML300 AND NON-COVALENT NANOMOLAR INHIBITORS WITH AN INDUCED-FIT BINDING |
)
)